Stefan Willmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1591908/publications.pdf

Version: 2024-02-01

73	3,819	147726 31	128225 60
papers	citations	h-index	g-index

74	74	74	2733
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. Journal of Clinical Pharmacology, 2022, 62, 220-231.	1.0	7
2	Modelâ€informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9â€‰years and older with congenital heart disease. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1111-1121.	1.3	3
3	Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxabanâ€"Renal and Hepatic Impairment and Drugâ€Drug Interaction Potential. Journal of Clinical Pharmacology, 2021, 61, 656-665.	1.0	21
4	Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. Frontiers in Pharmacology, 2021, 12, 630904.	1.6	5
5	PK/PD modeling of FXI antisense oligonucleotides to bridge the doseâ€FXI activity relation from healthy volunteers to endâ€stage renal disease patients. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 890-901.	1.3	22
6	Predictive Performance of Physiologyâ€Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Smallâ€Molecule Compounds in Children. Journal of Clinical Pharmacology, 2021, 61, S70-S82.	1.0	11
7	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 1018-1025.	0.3	5
8	Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologicallyâ€based pharmacokinetic predictions. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1195-1207.	1.3	7
9	Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets â€“ Implications for quality control and application. European Journal of Pharmaceutical Sciences, 2021, 166, 105940.	1.9	6
10	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€Jr phase 3 doseâ€exposureâ€response evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 1672-1685.	1.9	52
11	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 1-11.	1.0	10
12	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2020, 50, 20-29.	1.0	14
13	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 12-19.	1.0	6
14	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. Therapeutic Advances in Cardiovascular Disease, 2019, 13, 175394471986364.	1.0	6
15	Application of Physiologicallyâ€Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 654-663.	1.3	18
16	Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 805-814.	1.3	9
17	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematology,the, 2019, 6, e500-e509.	2.2	51
18	Predictive Pediatric Modeling and Simulation Using Ontogeny Information. Journal of Clinical Pharmacology, 2019, 59, S95-S103.	1.0	23

#	Article	IF	Citations
19	Pharmacokinetics, Safety, and Tolerability of Singleâ€Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study. Journal of Clinical Pharmacology, 2019, 59, 654-667.	1.0	12
20	Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 309-320.	1.3	51
21	Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections. Pediatric Infectious Disease Journal, 2018, 37, e207-e213.	1.1	20
22	Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Thrombosis Journal, 2018, 16, 32.	0.9	40
23	Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thrombosis Journal, 2018, 16, 31.	0.9	29
24	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. Blood Advances, 2018, 2, 3193-3195.	2.5	0
25	A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life. Clinical Pharmacokinetics, 2018, 57, 1613-1634.	1.6	25
26	Pharmacodynamics, Pharmacokinetics and Safety of Bay 1093884, an Antibody Directed Against Human TFPI, in Patients with Factor VIII or IX Deficiency (With and Without Inhibitors): A Phase 1 Study. Blood, 2018, 132, 1176-1176.	0.6	8
27	Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clinical Pharmacokinetics, 2017, 56, 1525-1541.	1.6	63
28	Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clinical Pharmacokinetics, 2017, 56, 1303-1330.	1.6	81
29	Addressing Adherence Using Genotype-Specific PBPK Modelingâ€"Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Frontiers in Pharmacology, 2017, 8, 67.	1.6	3
30	Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 516-531.	1.3	232
31	Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clinical Pharmacokinetics, 2016, 55, 1573-1589.	1.6	80
32	Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds. British Journal of Clinical Pharmacology, 2016, 81, 137-147.	1.1	31
33	Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data. Current Pharmaceutical Design, 2015, 21, 5688-5698.	0.9	59
34	Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban. Clinical Pharmacokinetics, 2014, 53, 89-102.	1.6	70
35	Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling. SpringerPlus, 2014, 3, 285.	1.2	12
36	Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacology, 2013, 1, 6.	1.8	41

#	Article	IF	Citations
37	Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study. Clinical Drug Investigation, 2013, 33, 419-427.	1.1	72
38	Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation. Journal of Pharmaceutical Sciences, 2013, 102, 3205-3219.	1.6	32
39	A Detailed Physiologically Based Model to Simulate the Pharmacokinetics and Hormonal Pharmacodynamics of Enalapril on the Circulating Endocrine Renin-Angiotensin-Aldosterone System. Frontiers in Physiology, 2013, 4, 4.	1.3	13
40	Pharmacogenomics of Codeine, Morphine, and Morphine-6-Glucuronide. Molecular Diagnosis and Therapy, 2012, 16, 43-53.	1.6	33
41	Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance. Frontiers in Pharmacology, 2012, 3, 92.	1.6	30
42	First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 195-203.	0.8	54
43	Prediction of a potentially effective dose in humans for BAY 60â€“5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologicallyâ€based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 2012, 73, 219-231.	1.1	12
44	Integration of dissolution into physiologically-based pharmacokinetic models III: PK-SimÂ®. Journal of Pharmacy and Pharmacology, 2012, 64, 997-1007.	1.2	43
45	Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part II: Extension to Describe Performance of Solid Dosage Forms. Journal of Pharmaceutical Sciences, 2012, 101, 1267-1280.	1.6	67
46	Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Cancer Chemotherapy and Pharmacology, 2012, 69, 397-405.	1.1	31
47	Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Molecular Diagnosis and Therapy, 2012, 16, 43-53.	1.6	17
48	An update on computational oral absorption simulation. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1345-1364.	1.5	20
49	A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks. Frontiers in Physiology, 2011, 2, 4.	1.3	167
50	Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions. Journal of Pharmaceutical Sciences, 2011, 100, 5324-5345.	1.6	111
51	Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. Journal of Pharmacy and Pharmacology, 2010, 61, 891-899.	1.2	24
52	Analysis of Nifedipine Absorption from Soft Gelatin Capsules Using PBPK Modeling and Biorelevant Dissolution Testing. Journal of Pharmaceutical Sciences, 2010, 99, 2899-2904.	1.6	26
53	Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 83-94.	2.0	62
54	Risk to the Breast-Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study. Clinical Pharmacology and Therapeutics, 2009, 86, 634-643.	2.3	122

#	Article	IF	Citations
55	Defining the Role of Macrophages in Local Moxifloxacin Tissue Concentrations using Biopsy Data and Whole-Body Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics, 2009, 48, 181-187.	1.6	18
56	Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. Journal of Pharmacy and Pharmacology, 2009, 61, 891-899.	1.2	10
57	Physiology-Based Simulations of a Pathological Condition. Clinical Pharmacokinetics, 2008, 47, 743-752.	1.6	144
58	Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1143-1152.	1.5	133
59	Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theoretical Biology and Medical Modelling, 2007, 4, 13.	2.1	55
60	Development and Validation of a Physiology-based Model for the Prediction of Oral Absorption in Monkeys. Pharmaceutical Research, 2007, 24, 1275-1282.	1.7	45
61	Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 401-431.	0.8	199
62	A Mechanistic Approach for the Scaling of Clearance in Children. Clinical Pharmacokinetics, 2006, 45, 683-704.	1.6	186
63	Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children. Clinical Pharmacokinetics, 2006, 45, 1013-1034.	1.6	288
64	Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions. Advances in Therapy, 2006, 23, 143-158.	1.3	17
65	Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paediatric and Perinatal Drug Therapy, 2006, 7, 146-153.	0.6	30
66	From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opinion on Drug Metabolism and Toxicology, 2005, 1, 159-168.	1.5	115
67	Physiology-based pharmacokinetic modeling: ready to be used. Drug Discovery Today: Technologies, 2005, 2, 125-132.	4.0	23
68	Physiology-based pharmacokinetic modeling: ready to be used. Drug Discovery Today: Technologies, 2004, 1, 449-456.	4.0	32
69	A Physiological Model for the Estimation of the Fraction Dose Absorbed in Humans. Journal of Medicinal Chemistry, 2004, 47, 4022-4031.	2.9	202
70	Glucose Quantification in Dried-down Nanoliter Samples Using Mid-Infrared Attenuated Total Reflection Spectroscopy. Applied Spectroscopy, 2004, 58, 442-450.	1.2	20
71	A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats. Pharmaceutical Research, 2003, 20, 1766-1771.	1.7	88
72	PK-SimÂ®: a physiologically based pharmacokinetic â€˜whole-bodyâ€™ model. Biosilico, 2003, 1, 121-124.	0.5	136

#	Article	IF	Citations
73	Small-volume frequency-domain oximetry: phantom experiments and first in vivo results. Journal of Biomedical Optics, 2003, 8, 618.	1.4	6